Formula Grant R43IP001229

This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...

The National Science Foundation awarded a $255,981 Small Business Innovation Research Phase I Project Grant to Frezent Biological Solutions Inc. of Valhalla, NY under the Engineering (CFDA 47.041) federal grant program. The grant funds the development of a novel peptide inhibitor of the coronavirus papain-like protease as a prophylactic and antiviral therapeutic for COVID-19, to be administered via inhalation. The Engineering program seeks to improve quality of life and economic strength...

The National Science Foundation Division of Industrial Innovation awarded $255,700 to Creative Biotherapeutics LLC through its Engineering program (CFDA 47.041) on January 15, 2021 to fund the project "SBIR PHASE I: STRESS PATHWAY INHIBITION PREVENTS COVID-19 INFECTION (COVID-19)." This Project Grant will support Creative Biotherapeutics' research efforts through December 31, 2021 to develop inhibitors of stress response pathways to prevent COVID-19 infection. The NSF Engineering...

Phenotarget Biosciences Inc. was awarded a $255,473 Project Grant from the National Science Foundation Division of Industrial Innovation under the Engineering (47.041) federal grant program. The grant supports discovery and development of macrocyclic peptide inhibitors of SARS-CoV-2 spike protein for the treatment of COVID-19 from July 1, 2021 through March 31, 2022. The Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in...

The National Institute of Allergy and Infectious Diseases awarded Sciogen LLC $314,363 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel therapeutics targeting respiratory syncytial virus (RSV) infection through G-receptor binding inhibition. The Phase I Small Business Innovation Research award funds evaluation of a new class of RSV inhibitors identified through high-throughput screening. Work includes assessment of biological...

This $788,406 project grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases, under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund the development of a sensitive, direct reading bioaerosol detection platform to quantify airborne pathogens such as SARS-CoV-2. Aerosol Devices Inc. will integrate their gentle condensation-growth capture sampler, which concentrates intact, viable virus particles into a small liquid volume...

The National Institute of Allergy and Infectious Diseases awarded Autonomous Therapeutics Inc. $1.981 million on September 10, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance a Phase II SBIR project translating AT191, an inhaled encrypted RNA (EncRNA) therapeutic candidate designed to prevent hospitalizations and deaths from SARS-CoV-2 variants. AT191 is a self-administered antiviral employing a platform-derived, first-in-class EncRNA technology that...

The National Science Foundation awarded a $256,000 Small Business Innovation Research Phase I Project Grant to White Rock Therapeutics under the Engineering federal grant program (CFDA 47.041). The grant will support development of an ACE2 decoy as a pan-coronavirus therapeutic from January 2022 to December 2022. The Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research. This award will fund initial research...

Neyroblastgx LLC was awarded a $255,997 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program. The grant will support the company's research efforts to genetically engineer dendritic cells to activate T cells specific to the SARS-CoV-2 spike protein, with the goal of developing a novel approach to treating COVID-19. The research is expected to be conducted between April 2021 and December 2022. The NSF Technology, Innovation, and...

The National Institute of Allergy and Infectious Diseases awarded Partillion Bioscience Corp $306,865 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop nanovial-based technologies for accelerated monoclonal antibody discovery and characterization. Partillion will engineer novel nanovial formulations to enable streptavidin-antigen complexes as detection agents, increasing the multiplexing capacity of single-cell antibody screening assays. The...